The results showed that GC patients in the KLF2 mutant group had poorer disease-free survival (Figure 2(c)), disease-specific survival (Figure 2(d)), overall survival (Figure 2(e)), and progression-free survival (Figure 2(f)) compared with the nonmutant group, but there was no significant difference (P > 0.05). This evidence concerns the gene KLF2 and gastric cancer.